Claims for Patent: 9,493,571

Summary for Patent: 9,493,571

Title:	Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
Abstract:	Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	15/182,378
Patent Claims:	1. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis of a knee. 2. The method of claim 1, wherein the human being experiences pain relief at three months after the denosumab is first administered. 3. The method of claim 1, wherein about 30 mg to about 180 mg of denosumab is administered to the human being no more than once a week. 4. The method of claim 1, wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent. 5. The method of claim 1, further comprising administration of an analgesic or an anti-inflammatory agent. 6. The method of claim 5, wherein the analgesic agent is a narcotic pain reliever, an opioid pain reliever, a steroid, acetaminophen, morphine, codeine, fentanyl, oxycodone, hydrocodone, hydromorphone, triamcinolone, prednisone, methylprednisolone, or cortisone. 7. The method of claim 1, wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab. 8. The method of claim 1, wherein the denosumab is administered by injection. 9. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting a hip. 10. The method of claim 9, wherein the human being experiences pain relief at three months after the denosumab is first administered. 11. The method of claim 9, wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being within a four week period. 12. The method of claim 9, wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent. 13. The method of claim 9, further comprising administration of an analgesic or an anti-inflammatory agent. 14. The method of claim 13, wherein the anti-inflammatory agent is an nonsterioidal anti-inflammatory drug (NSAID), ibuprofen, naproxen, ketoprofen, celecoxib, firocoxib, or meloxicam. 15. The method of claim 9, wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab. 16. The method of claim 9, wherein the denosumab is administered by injection. 17. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting an elbow, a wrist, or a finger. 18. The method of claim 17, wherein the human being experiences pain relief at three months after the denosumab is first administered. 19. The method of claim 17, wherein about 0.5 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a three to five week period. 20. The method of claim 17, wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent. 21. The method of claim 17, further comprising administration of an analgesic or an anti-inflammatory agent. 22. The method of claim 17, wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab. 23. The method of claim 17, wherein the denosumab is administered by injection. 24. A method of treating pain comprising administering denosumab to a human being suffering from osteoarthritis affecting a shoulder. 25. The method of claim 24, wherein the human being experiences pain relief at three months after the denosumab is first administered. 26. The method of claim 24, wherein about 30 mg to about 150 mg of denosumab is administered to the human being no more than once a week. 27. The method of claim 24, wherein the denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent. 28. The method of claim 24, further comprising administration of an analgesic or an anti-inflammatory agent. 29. The method of claim 24, wherein the denosumab is administered in a liquid composition comprising about 1% (w/v) to about 20% (w/v) of denosumab. 30. The method of claim 24, wherein the denosumab is parenterally administered.

Details for Patent 9,493,571

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2034-06-11
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2034-06-11